MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SNY stock logo

SNY

Sanofi

$45.65
0.11
 (0.23%)
Exchange:  
Market Cap:   113.15B
Shares Outstanding:   730.784M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Paul Hudson
Full Time Employees:  82878
Address: 
54, Rue La BoEtie
Paris
75008
FR
Website:  https://www.sanofi.com
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Click to read more…

Revenue Segmentation

πŸ”’ You are currently logged out

Login

It’s free

EPS

πŸ”’ You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

πŸ”’ You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

It’s free

Current Key Metrics

πŸ”’ You are currently logged out

Login

It’s free

Forward P/E Ratios

πŸ”’ You are currently logged out

Login

It’s free

SWOT Analysis

πŸ”’ You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator


Calculate SNY Intrinsic Value

πŸ”’ You are currently logged out

Login

It’s free

See in Nexus

Relevant news

26-09-2025 13:40
Sanofi Expands Insulin Savings Program To Cover All US Patients
26-09-2025 08:26
Sanofi to offer all insulin products for $35 per month in US
24-09-2025 08:49
French court orders Sanofi to pay $177 million for anti-competitive behaviour
24-09-2025 01:05
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24-09-2025 01:00
Press release: Availability of the Q3 2025 Aide mΓ©moire
23-09-2025 01:00
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read